RecruitingPhase 1NCT06751238

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis

Sponsor

Novartis Pharmaceuticals

Enrollment

20 participants

Start Date

Sep 24, 2025

Study Type

INTERVENTIONAL

Conditions

Juvenile Psoriatic Arthritis

Summary

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

Eligibility

Min Age: 2 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Secukinumab for people with juvenile psoriatic arthritis. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 2 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSecukinumab

Intravenous secukinumab

Locations(11)

Loma Linda University Health

Loma Linda, California, United States

University of Florida

Gainesville, Florida, United States

Ann and Robert H Lurie Childs Hosp

Chicago, Illinois, United States

Col Uni Med Center New York Presby

New York, New York, United States

Levine Childrens Hospital

Charlotte, North Carolina, United States

Cincinnati Childrens Hospital

Cincinnati, Ohio, United States

Univ Hosp Cleveland Medical Center

Cleveland, Ohio, United States

Legacy Emanuel Research Hosp Portland

Portland, Oregon, United States

Childrens Hosp Pittsburgh UPMC

Pittsburgh, Pennsylvania, United States

Texas Arthritis Center

El Paso, Texas, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06751238

Related Trials

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT0610074434 locations

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT0686955147 locations

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT0666818123 locations

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

NCT057670477 locations